Search

Displaying results 1691 - 1700 of 10000 in total
  1. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.

  2. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008. … Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.

  3. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile. … Etoperidone is an atypical antidepressant introduced in Europe in 1977.

  4. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS. … Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe

    Synonyms: from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a
  5. Drug

    Trimetrexate

    go.drugbank.com/drugs/DB01157
    Approved

    A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. … It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

  6. Drug

    Profenamine

    go.drugbank.com/drugs/DB00392
    Approved

    Profenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. … It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]

    Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamine
  7. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … It targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515].

    Synonyms: (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamide
  8. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … [L44181] Hemophilia B is the second most common type of hemophilia,[L44181] with a prevalence of approximately one in 40,000.

  10. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    Zilganersen is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide used to treat Alexander disease. … [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons